

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/tgh-22-12	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	De-identified information collected from the electronic health record of all study participants within an excel file including patient demographics, laboratory values, etiology of liver disease (including non-alcoholic fatty liver disease, alcohol-related, hepatitis C virus, autoimmune, primary sclerosing/biliary cholangitis, cardiac, vascular, and idiopathic), diagnosis of cirrhosis, calculated MELD-Na scores at time of vaccination, use of immunosuppressive medications, medical comorbidities (including chronic kidney disease, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery disease, hypertension, hypothyroidism, HIV infection, and malignancy), and body mass index.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	None
5	When will data availability begin?	From the publication date
6	When will data availability end?	5 years from the publication date
7	To whom will you share the data?	Medical professionals who are interested in the topic (hepatitis B vaccination in patients with chronic liver disease).

8	For what type of analysis or purpose?	For analysis to evaluate the efficacy of Hepatitis B vaccination in patients with chronic liver disease
9	How or where can the data/documents be obtained?	Emails could be sent to kwon.joshua@mayo.edu
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.